Skip to content
Guess what? Valuesider just got better: smarter and more intuitive.
Impax Laboratories Inc

IPXL

Impax Laboratories Inc

Impax Laboratories Inc historical holders

total: 1

Tiger Global Management Impax Laboratories Inc transactions over time

Total transactions:
2
New positions:
1
Sold out:
1
Held since:
2015 Q2
Held for:
1 quarter
Latest activity:
2015 Q3
Chase Coleman III has been an institutional investor in Impax Laboratories Inc (IPXL) since 2015 Q2. According to 2026 Q1 report, Chase Coleman III doesn't hold any shares. The fund/company first acquired IPXL in 2015 Q2, initially purchasing 430,000 shares. Since the initial investment, Tiger Global Management has made 1 more transaction in this position.

When did Chase Coleman III exit their IPXL position?

Chase Coleman III no longer holds Impax Laboratories Inc (IPXL). They sold off their entire position in 2015 Q3, closing out an investment that began in 2015 Q2.

When did Chase Coleman III first invest in IPXL?

Chase Coleman III first invested in Impax Laboratories Inc (IPXL) in 2015 Q2 at the reported quarter-end price of $45.92 per share, acquiring 430,000 shares in their initial purchase.

What is Chase Coleman III's average cost basis for IPXL?

Based on historical transaction data, Chase Coleman III's estimated cost basis for Impax Laboratories Inc (IPXL) is approximately $45.92 per share. This represents their average reported price* across all buy transactions.

Estimated cost basis*

Weighted AVG buy price:
$45.92
Weighted AVG sell price:
$45.92

IPXL transactions history by Tiger Global Management

2 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2015 Q3
0.00%
$45.92
-100% (-430,000)
2015 Q2
0.20%
$45.92
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.